Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. (CRNX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.93 (rule-based classification). Capital structure on the latest snapshot: total assets 1,401,323,000 USD, total equity 1,280,646,000, short-term debt 0, long-term debt 0. Net cash position is approximately 1,291,306,000 USD. Self-calculated market cap is 4,375,280,970 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 10,734,000, gross profit 0, operating income -140,378,000, net income -127,845,000. Return on equity ~-36.3%. Return on assets ~-33.2%. Operating-cash-flow to net-income ratio is 0.81. Risk profile from automated assessment: liquidity risk low, dilution risk medium. Flags: Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] 8-K: 8-K (sec_8k_material) on CRNX — filing_type=8-K; max_severity=high; ignored_items=['8.01', '9.01']; material_items=['1.01']; all_items_found=['1.01', '8.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001140361-26-027642). Additional context: 8-K: filing_type=8-K; max_severity=high; ignored_items=['8.01', '9.01']; material_items=['1.01']; all_items_found=['1.01', '8.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material.